Cécile Chartier
Director/Board Member presso CELLECTIS S.A.
Profilo
Cécile Chartier is currently working as a Director at Cellectis SA and as the Chief Scientific Officer at NextVivo, Inc. She holds a doctorate degree from Universite Louis Pasteur Strasbourg I.
Posizioni attive di Cécile Chartier
Società | Posizione | Inizio |
---|---|---|
CELLECTIS S.A. | Director/Board Member | 27/06/2023 |
NextVivo, Inc.
NextVivo, Inc. Packaged SoftwareTechnology Services NextVivo, Inc. is a biotech company based in California that is focused on developing an immune organoid technology platform to accelerate the development of safer and more effective therapies. The American company's mission is to generate and test immune-competent human-derived models that can be used to develop cell and antibody therapies and test immune-modulating drug candidates for a range of diseases, including cancer, infection, and autoimmune disorders. The company was co-founded by Dr. Mark Davis and Dr. Calvin Kuo from Stanford University, and by Dr. Adam Margolin, former chair and professor of genetics and genomic science and senior associate dean. Dr. Adam Margolin has been the CEO since incorporation. | Chief Tech/Sci/R&D Officer | - |
Formazione di Cécile Chartier
Universite Louis Pasteur Strasbourg I | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
CELLECTIS S.A. | Health Technology |
Aziende private | 1 |
---|---|
NextVivo, Inc.
NextVivo, Inc. Packaged SoftwareTechnology Services NextVivo, Inc. is a biotech company based in California that is focused on developing an immune organoid technology platform to accelerate the development of safer and more effective therapies. The American company's mission is to generate and test immune-competent human-derived models that can be used to develop cell and antibody therapies and test immune-modulating drug candidates for a range of diseases, including cancer, infection, and autoimmune disorders. The company was co-founded by Dr. Mark Davis and Dr. Calvin Kuo from Stanford University, and by Dr. Adam Margolin, former chair and professor of genetics and genomic science and senior associate dean. Dr. Adam Margolin has been the CEO since incorporation. | Technology Services |
- Borsa valori
- Insiders
- Cécile Chartier